Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Emmessar Biotech & Nutrition has submitted copies of its Q1 FY26 (quarter ended June 30, 2025) audited financial results that were published in Free Press Journal and Nav Shakti newspapers on August 8, 2025, as required under SEBI Listing Regulations. The results were taken on record by the Board of Directors at their meeting held on August 8, 2025 and have been subjected to a limited review by the statutory auditors. The company reports its business across two segments: Healthcare and Rent on Leasehold Land. No investor complaints were received during the quarter. The signed letter was filed by Priyanka Sharma, Company Secretary. The specific numerical figures for Emmessar are not clearly extractable from the OCR'd newspaper content provided.
This is a routine regulatory compliance filing confirming that Q1 FY26 audited results have been publicly disclosed via newspapers. No new business update, dividend, or material change is announced, so no direct share price catalyst is expected from this filing alone.